Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230181908> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4230181908 endingPage "187" @default.
- W4230181908 startingPage "182" @default.
- W4230181908 abstract "Diaziquone given as a bolus has not been effective in patients with relapsed or refractory leukemia. Because of in vitro data suggesting enhancement of diaziquone-induced cytotoxicity for human and murine leukemia cells with increased duration of drug exposure and the relatively short terminal plasma half-life of diaziquone, 49 patients (34 acute nonlymphocytic leukemia [ANLL], six chronic myelogenous leukemia in blast crisis [CML-B], five acute lymphocytic leukemia [ALL], four 2 degrees ANLL) with leukemia were given diaziquone as a continuous infusion for seven days. The maximum tolerated dose was 28 mg/m2/d for seven days. The dose-limiting toxicity was the duration of bone marrow aplasia (median, 49 days to greater than 500 PMNs in responders; range, 28 to 101 days). Nonhematologic toxicity was minimal. Responses occurred only in patients with relapsed ANLL, of whom 26 were treated at effective doses. There were six complete responses (CR) (23%) and two partial responses (PR) (8%), although five of eight responders never achieved platelet counts greater than 100,000/microL. Thrombocytopenia in these patients was felt to be a manifestation of diaziquone effect, not persistence of leukemia. The median duration of CR was 195 days (range, 88 to 860+). One patient had active CNS leukemia at the start of treatment and has had a durable (28+ month) CR in both sites of disease. Diaziquone produced prolonged aplasia in patients with secondary ANLL and CML-B (five of ten patients died aplastic), whereas patients with ALL all had regrowth of leukemia and two failed to become aplastic. The lack of significant nonhematologic toxicity and the activity in patients with relapsed ANLL render diaziquone of interest as second-line therapy or consolidation therapy in first remission for patients with ANLL." @default.
- W4230181908 created "2022-05-11" @default.
- W4230181908 creator A5030728940 @default.
- W4230181908 creator A5040833135 @default.
- W4230181908 creator A5052762910 @default.
- W4230181908 creator A5062604947 @default.
- W4230181908 creator A5070245891 @default.
- W4230181908 creator A5091510495 @default.
- W4230181908 date "1986-01-01" @default.
- W4230181908 modified "2023-09-27" @default.
- W4230181908 title "Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia" @default.
- W4230181908 doi "https://doi.org/10.1182/blood.v67.1.182.bloodjournal671182" @default.
- W4230181908 hasPublicationYear "1986" @default.
- W4230181908 type Work @default.
- W4230181908 citedByCount "0" @default.
- W4230181908 crossrefType "journal-article" @default.
- W4230181908 hasAuthorship W4230181908A5030728940 @default.
- W4230181908 hasAuthorship W4230181908A5040833135 @default.
- W4230181908 hasAuthorship W4230181908A5052762910 @default.
- W4230181908 hasAuthorship W4230181908A5062604947 @default.
- W4230181908 hasAuthorship W4230181908A5070245891 @default.
- W4230181908 hasAuthorship W4230181908A5091510495 @default.
- W4230181908 hasBestOaLocation W42301819081 @default.
- W4230181908 hasConcept C126322002 @default.
- W4230181908 hasConcept C141071460 @default.
- W4230181908 hasConcept C2776694085 @default.
- W4230181908 hasConcept C2776960273 @default.
- W4230181908 hasConcept C2778368355 @default.
- W4230181908 hasConcept C2778461978 @default.
- W4230181908 hasConcept C2780007613 @default.
- W4230181908 hasConcept C2781107101 @default.
- W4230181908 hasConcept C2909962599 @default.
- W4230181908 hasConcept C2911114841 @default.
- W4230181908 hasConcept C29730261 @default.
- W4230181908 hasConcept C71924100 @default.
- W4230181908 hasConcept C90924648 @default.
- W4230181908 hasConceptScore W4230181908C126322002 @default.
- W4230181908 hasConceptScore W4230181908C141071460 @default.
- W4230181908 hasConceptScore W4230181908C2776694085 @default.
- W4230181908 hasConceptScore W4230181908C2776960273 @default.
- W4230181908 hasConceptScore W4230181908C2778368355 @default.
- W4230181908 hasConceptScore W4230181908C2778461978 @default.
- W4230181908 hasConceptScore W4230181908C2780007613 @default.
- W4230181908 hasConceptScore W4230181908C2781107101 @default.
- W4230181908 hasConceptScore W4230181908C2909962599 @default.
- W4230181908 hasConceptScore W4230181908C2911114841 @default.
- W4230181908 hasConceptScore W4230181908C29730261 @default.
- W4230181908 hasConceptScore W4230181908C71924100 @default.
- W4230181908 hasConceptScore W4230181908C90924648 @default.
- W4230181908 hasIssue "1" @default.
- W4230181908 hasLocation W42301819081 @default.
- W4230181908 hasOpenAccess W4230181908 @default.
- W4230181908 hasPrimaryLocation W42301819081 @default.
- W4230181908 hasRelatedWork W1490390872 @default.
- W4230181908 hasRelatedWork W1886571167 @default.
- W4230181908 hasRelatedWork W1979785276 @default.
- W4230181908 hasRelatedWork W2008234626 @default.
- W4230181908 hasRelatedWork W2088394051 @default.
- W4230181908 hasRelatedWork W2413805101 @default.
- W4230181908 hasRelatedWork W2416295860 @default.
- W4230181908 hasRelatedWork W4230181908 @default.
- W4230181908 hasRelatedWork W54147411 @default.
- W4230181908 hasRelatedWork W2103761397 @default.
- W4230181908 hasVolume "67" @default.
- W4230181908 isParatext "false" @default.
- W4230181908 isRetracted "false" @default.
- W4230181908 workType "article" @default.